Boston Scientific gains WallFlex esophageal stent clearance
This article was originally published in The Gray Sheet
Firm gains 510(k) clearance and CE-mark approval for its WallFlex fully covered esophageal stent, designed to treat malignant esophageal obstructions caused by tumors in patients with esophageal cancer, the firm announces Nov. 20. A partially covered version of the self-expanding esophageal stent debuted in 2008. The devices employ a proprietary Permalume silicone covering to prevent tumor ingrowth, seal concurrent esophageal strictures and help reduce food impaction, the company explains
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.